Clinical Trials Results - National Cancer Institute

Skip to content

National Cancer Institute
U.S. National Institutes of Health | www.cancer.gov


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?


	1-800-4-CANCER

	LiveHelp® online chat

	NCI Highlights


	Virtual and Standard Colonoscopy Both Accurate Denosumab May Help Prevent Bone Loss Past Highlights



Results: 1 -5 of 5 Show results per page	View Search Criteria \| Help With Results


Sort By:	Version:	Format:


1.		Study of MAGE-A3 and NY-ESO-1 Immunotherapy in Combo With DTPACE Chemo and Auto Transplantation in Multiple Myeloma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III, Phase II				Treatment				Active				18 to 70				Other				UARK 2003-26 NCT00090493

Last Modified: 9/19/2007 First Published: 4/7/2006


2.		Phase I/II Randomized Study of Vaccination Comprising MART-1/gp100/Tyrosinase/NY-ESO-1/MAGE-3 Peptide-Pulsed Dendritic Cells Matured Using Cytokines in Combination With Autologous Lymphocyte Infusion With or Without Fludarabine in Patients With Chemotherapy-Naïve Metastatic Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				16 and over				NCI				MCC-13649 LAC-USC-10M-05-2, 6241, NCI-6241, LAC-USC-HS-05-00068, NCT00313508


3.		Study of NY-ESO-1 ISCOMATRIX® in Patients With Measurable Stage III or IV Melanoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				LUD2002-013 CTN Trial No.: 2007/123, CTN-Protocol# LUD2002-013AMEND, NCT00518206


4.		Immunotherapy of Stage III/IV Melanoma Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				LUD 2001-003 NCT00112242


5.		A Phase I Study of NY-ESO-1 Overlapping Peptides (OLP4) With or Without Montanide Vaccination of Epithelial Ovarian Cancer (EOC), Fallopian Tube, or Primary Peritoneal Cancer Patients in Second or Third Remission

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Active				18 and over				Other				LUD2006-001 MSKCC IRB# 07-152, NCT00616941

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute